Search Result

Results for "

targets CEACAM5

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (2) Antibody-Drug Conjugates (ADCs) (1) Microtubule/Tubulin (1) Radionuclide-Drug Conjugates (RDCs) (1) Transmembrane Glycoprotein (8)
By Research Areas:	Cancer (8) Inflammation/Immunology (3)

Inhibitors & Agonists

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99054

Tusamitamab SAR-408377; PF-08046050 Antibody; SAR445953 Antibody	Transmembrane Glycoprotein ADC Antibody	Cancer
Tusamitamab is an IgG1 monoclonal antibody that targets *CEACAM5*. Tusamitamab can be used to synthesize ADC Tusamitamab ravtansine (SAR408701) (HY-P99542) .

HY-P99542

Tusamitamab ravtansine SAR-408701; HuMAb2-3-SPDB-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing *CEACAM5, composed of a humanized anti-CEACAM5* monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .

HY-164899

2A3 2-aminopyridine-3-carboxylic acid imidazolide	Transmembrane Glycoprotein	Cancer
2A3 (2-aminopyridine-3-carboxylic acid imidazolide) is a T cell activator that specifically binds to *CEACAM6* and *CEACAM5. 2A3 exhibits enzymatic activity that catalyzes the glucuronidation of specific substrates (e.g., 1-naphthol), and possesses significant cytotoxic activity. When integrated into CAR T cells or used alone, 2A3 acts by inducing cytokine release, degranulation, and direct cytotoxicity. 2A3 kills pancreatic and breast cancer cells with high target* antigen expression in vitro, and significantly inhibits the growth of pancreatic cancer xenografts in vivo. 2A3 broadly targets malignant tumors with overexpressed CEACAM5, CEACAM6, or co-expressed both, and shows high expression mainly in tissues such as the liver and colon. 2A3 serves as an important research tool for the immunotherapy of pancreatic and breast cancer . 2A3 is a novel SHAPE reagent, which can be used for the analysis of RNA structure both in vitro and in vivo . 2A3 is an electrophilic chemical probe that acylates the 2'-OH in the RNA backbone. 2A3 can be used for RNA SHAPE-MaP experiments and is capable of analyzing the RNA secondary structures at single nucleotide resolution.

HY-P991060

Cergutuzumab	Transmembrane Glycoprotein	Cancer
Cergutuzumab is a fully human IgG1 antibody that targets carcinoembryonic antigen (CEA, *CEACAM5, CD66e*). Cergutuzumab can be used to form the recombinant protein Cergutuzumab amunaleukin (HY-P99498) .

HY-P991469

AMG-211 MEDI-565	Transmembrane Glycoprotein	Cancer
AMG-211 (MEDI-565)i s a bispecific antibody targeting CD3E and *CEACAM5/CEA/CD66e*. AMG-211 can be used in Gastrointestinal cancer and Solid tumours research .

HY-P990853

Anti-CEACAM5 Antibody (4H11-8)	Transmembrane Glycoprotein	Cancer
Anti-CEACAM5 Antibody (4H11-8) is a kind of mouse IgG1 κ chimeric antibody, targeting to human *CEACAM5. Anti-CEACAM5* Antibody (4H11-8) reacts with human CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5). Anti-CEACAM5 Antibody (4H11-8) can be used for detecting CEACAM5 in cancer.

HY-P992090

Altumomab	Radionuclide-Drug Conjugates (RDCs) Transmembrane Glycoprotein	Inflammation/Immunology
Altumomab is a anti-huamn monoclonal antibody targeting *CEACAM5/CEA/CD66e* .

HY-P992350

EBC-129 Antibody	ADC Antibody Transmembrane Glycoprotein	Cancer
EBC-129 Antibody is a specific antibody for the synthetic antibody-drug conjugate (ADC) EBC-129, which specifically targets *CEACAM5* and *CEACAM6* glycosylated at N256. EBC-129 Antibody can be used for the research of pancreatic ductal adenocarcinoma .

HY-P992344

DNP002	Transmembrane Glycoprotein	Cancer
DNP002 is a humanized IgG1 monoclonal antibody targeting tumor-associated *CEACAM6. DNP002 binds to CEACAM1, CEACAM5* and *CEACAM6, and exhibits antibody-dependent cellular cytotoxicity against tumor cells overexpressing these targets. DNP002 binds to CEACAM6* on the surface of tumor-associated neutrophils (including MDSCs) to reverse the immunosuppressive effect in the tumor microenvironment. DNP002 shows anti-tumor activity in advanced solid tumors. DNP002 can be used for the research of advanced solid tumors. The recommended isotype control is human IgG1 kappa (HY-P99001) .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99054

Tusamitamab SAR-408377; PF-08046050 Antibody; SAR445953 Antibody	Transmembrane Glycoprotein ADC Antibody	Cancer
Tusamitamab is an IgG1 monoclonal antibody that targets *CEACAM5*. Tusamitamab can be used to synthesize ADC Tusamitamab ravtansine (SAR408701) (HY-P99542) .

HY-P99542

Tusamitamab ravtansine SAR-408701; HuMAb2-3-SPDB-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing *CEACAM5, composed of a humanized anti-CEACAM5* monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .

HY-P990940

Precemtabart MBE-748; M-9140 Antibody; MBE-2882 Antibody	Inhibitory Antibodies	Inflammation/Immunology
HY-P990940 is an *CEACAM5*-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991060

Cergutuzumab	Transmembrane Glycoprotein	Cancer
Cergutuzumab is a fully human IgG1 antibody that targets carcinoembryonic antigen (CEA, *CEACAM5, CD66e*). Cergutuzumab can be used to form the recombinant protein Cergutuzumab amunaleukin (HY-P99498) .

HY-P991469

AMG-211 MEDI-565	Transmembrane Glycoprotein	Cancer
AMG-211 (MEDI-565)i s a bispecific antibody targeting CD3E and *CEACAM5/CEA/CD66e*. AMG-211 can be used in Gastrointestinal cancer and Solid tumours research .

HY-P991563

Anti-CEACAM5 Antibody (A5B7)	Inhibitory Antibodies	Others
Anti-CEACAM5 Antibody (A5B7) is a humanized antibody expressed in CHO cells, targeting *CEACAM5/CEA/CD66e. Anti-CEACAM5* Antibody (A5B7) consists of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CEACAM5 Antibody (A5B7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990853

Anti-CEACAM5 Antibody (4H11-8)	Transmembrane Glycoprotein	Cancer
Anti-CEACAM5 Antibody (4H11-8) is a kind of mouse IgG1 κ chimeric antibody, targeting to human *CEACAM5. Anti-CEACAM5* Antibody (4H11-8) reacts with human CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5). Anti-CEACAM5 Antibody (4H11-8) can be used for detecting CEACAM5 in cancer.

HY-P992090

Altumomab	Radionuclide-Drug Conjugates (RDCs) Transmembrane Glycoprotein	Inflammation/Immunology
Altumomab is a anti-huamn monoclonal antibody targeting *CEACAM5/CEA/CD66e* .

HY-P990365

Anti-CEACAM5/CEA/CD66e Antibody	Inhibitory Antibodies	Inflammation/Immunology
The Anti-CEACAM5/CEA/CD66e Antibody is a humanized antibody expressed in CHO cells, targeting *CEACAM5/CEA/CD66e. The Anti-CEACAM5/CEA/CD66e Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CEACAM5*/CEA/CD66e Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P992350

EBC-129 Antibody	ADC Antibody Transmembrane Glycoprotein	Cancer
EBC-129 Antibody is a specific antibody for the synthetic antibody-drug conjugate (ADC) EBC-129, which specifically targets *CEACAM5* and *CEACAM6* glycosylated at N256. EBC-129 Antibody can be used for the research of pancreatic ductal adenocarcinoma .

HY-P992344

DNP002	Transmembrane Glycoprotein	Cancer
DNP002 is a humanized IgG1 monoclonal antibody targeting tumor-associated *CEACAM6. DNP002 binds to CEACAM1, CEACAM5* and *CEACAM6, and exhibits antibody-dependent cellular cytotoxicity against tumor cells overexpressing these targets. DNP002 binds to CEACAM6* on the surface of tumor-associated neutrophils (including MDSCs) to reverse the immunosuppressive effect in the tumor microenvironment. DNP002 shows anti-tumor activity in advanced solid tumors. DNP002 can be used for the research of advanced solid tumors. The recommended isotype control is human IgG1 kappa (HY-P99001) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.